TWI916531B - 用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑 - Google Patents

用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑

Info

Publication number
TWI916531B
TWI916531B TW111109708A TW111109708A TWI916531B TW I916531 B TWI916531 B TW I916531B TW 111109708 A TW111109708 A TW 111109708A TW 111109708 A TW111109708 A TW 111109708A TW I916531 B TWI916531 B TW I916531B
Authority
TW
Taiwan
Prior art keywords
compound
acth
cortisol
disease
cushing
Prior art date
Application number
TW111109708A
Other languages
English (en)
Chinese (zh)
Other versions
TW202302108A (zh
Inventor
庫克 克莉絲汀 費拉拉
艾倫 Ｓ 克拉斯納
Original Assignee
美商克林提克斯醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商克林提克斯醫藥股份有限公司 filed Critical 美商克林提克斯醫藥股份有限公司
Publication of TW202302108A publication Critical patent/TW202302108A/zh
Application granted granted Critical
Publication of TWI916531B publication Critical patent/TWI916531B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111109708A 2021-03-19 2022-03-16 用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑 TWI916531B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163163310P 2021-03-19 2021-03-19
US63/163,310 2021-03-19
US202263298571P 2022-01-11 2022-01-11
US63/298,571 2022-01-11

Publications (2)

Publication Number Publication Date
TW202302108A TW202302108A (zh) 2023-01-16
TWI916531B true TWI916531B (zh) 2026-03-01

Family

ID=83321094

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111109708A TWI916531B (zh) 2021-03-19 2022-03-16 用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑

Country Status (11)

Country Link
US (2) US12280046B2 (enExample)
EP (1) EP4308553A4 (enExample)
JP (2) JP2024510260A (enExample)
KR (1) KR20230159443A (enExample)
AU (1) AU2022240609A1 (enExample)
BR (1) BR112023018816A2 (enExample)
CA (1) CA3211644A1 (enExample)
IL (1) IL305952A (enExample)
MX (1) MX2023010897A (enExample)
TW (1) TWI916531B (enExample)
WO (1) WO2022197798A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
EP4634176A1 (en) * 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist
PE20260134A1 (es) * 2023-05-19 2026-01-21 Crinetics Pharmaceuticals Inc Composiciones y metodos para el tratamiento de la hiperplasia suprarrenal congenita

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200010452A1 (en) 2018-06-05 2020-01-09 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US20030158209A1 (en) 2001-10-09 2003-08-21 Neurocrine Biosciences Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
EP1663232B1 (en) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
CA2625877A1 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PT2344474E (pt) 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2715754B1 (en) 2011-05-31 2015-07-29 Linak A/S Actuator
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
US11377436B2 (en) 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
WO2021091788A1 (en) 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
WO2023163945A1 (en) 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
EP4634176A1 (en) 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200010452A1 (en) 2018-06-05 2020-01-09 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Also Published As

Publication number Publication date
US20250367190A1 (en) 2025-12-04
US12280046B2 (en) 2025-04-22
CA3211644A1 (en) 2022-09-22
IL305952A (en) 2023-11-01
EP4308553A4 (en) 2025-01-22
AU2022240609A1 (en) 2023-09-28
JP2024510260A (ja) 2024-03-06
KR20230159443A (ko) 2023-11-21
US20220313691A1 (en) 2022-10-06
WO2022197798A1 (en) 2022-09-22
EP4308553A1 (en) 2024-01-24
MX2023010897A (es) 2023-09-27
TW202302108A (zh) 2023-01-16
BR112023018816A2 (pt) 2023-10-31
JP2026009936A (ja) 2026-01-21

Similar Documents

Publication Publication Date Title
US12280046B2 (en) Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
Mazziotti et al. Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects
Papierska et al. Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women
WO2007096782A2 (en) Compositions for disorders associated wtth metachromatic cell activation
JP2011021044A (ja) 片頭痛を処置するための方法
Bateman et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma
de Miguel Novoa et al. Guidelines for diagnosis and treatment of adrenal insufficiency in adults
JP2020033354A (ja) 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
US12290551B2 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
ZuWallack et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma
Yoon et al. Receptor-mediated muscle homeostasis as a target for sarcopenia therapeutics
JP2013543005A (ja) 線維筋痛症候群および慢性疲労症候群を処置する方法
WO2023163945A1 (en) Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
US12625150B2 (en) Treatment of, and differential diagnosis between, ACTH-dependent Cushing's syndrome and ACTH-independent Cushing's syndrome
JP2020530031A (ja) 前立腺癌治療における新しいアジュバント療法
Bagdy The role of biogenic amines in neuroendocrine regulation in conscious rats
Karmazin et al. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function.
EA052204B1 (ru) Применение антагониста рецептора меланокортина 2-го подтипа (mc2r) для лечения болезни кушинга или эктопического актг-синдрома (eas)
CN117043146A (zh) 用于治疗疾病的黑皮质素亚型-2受体（mc2r）拮抗剂
TW202506122A (zh) 用於治療ａｃｔｈ依賴性庫欣綜合征的黑素皮質素２型（ｍｃ２ｒ）受體拮抗劑
CA3122581C (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
Chitra et al. Pseudo-and latrogenic Cushing's Syndrome
Grady Pharmacokinetics and pharmacodynamics of oral dexamethasone in healthy horses
Mantovani Innovative Treatment Approach for Cancer-Related Cachexia